Verona Pharma plc
VRNA
$65.46
$0.681.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -218.96% | -203.27% | -142.89% | -4.64% | 20.86% |
| Total Depreciation and Amortization | 56.28% | 62.42% | 44.05% | 24.29% | 6.45% |
| Total Amortization of Deferred Charges | 1,024.14% | 331.69% | 45.00% | 45.00% | 45.00% |
| Total Other Non-Cash Items | 216.43% | 145.47% | 231.84% | 6.11% | -8.53% |
| Change in Net Operating Assets | 58.72% | 168.52% | 185.09% | -62.12% | -29.43% |
| Cash from Operations | -143.33% | -118.19% | -1.73% | -13.53% | 16.10% |
| Capital Expenditure | -- | -- | -- | 44.83% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | 44.83% | -- |
| Total Debt Issued | 216.47% | 656.21% | 656.21% | 43.59% | 287.08% |
| Total Debt Repaid | -- | -793.26% | -793.26% | -- | -- |
| Issuance of Common Stock | 74.83% | -92.51% | -99.59% | -99.53% | -61.06% |
| Repurchase of Common Stock | -229.65% | -578.30% | -200.40% | -110.25% | 0.74% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 775,808.33% | 47,586.22% | 1,099.03% | 96.15% | 99.88% |
| Cash from Financing | 170.04% | 152.74% | -11.03% | -89.98% | -34.05% |
| Foreign Exchange rate Adjustments | -100.85% | 5.82% | -101.00% | 213.19% | 187.70% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 191.24% | 206.54% | -15.92% | -123.03% | -44.69% |